Roivant Sciences (ROIV) Total Debt (2021 - 2024)
Roivant Sciences' (ROIV) quarterly Total Debt came in at $323.7 million in Q2 2024, down 17.51% YoY from $392.4 million in Q3 2023, and down 26.86% on a QoQ basis from $442.6 million in Q1 2024.
Roivant Sciences (ROIV) Total Debt (2021 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 4 years of Total Debt data on file, last reported at $323.7 million in Q2 2024.
- Quarterly Total Debt fell 17.51% year-over-year to $323.7 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $323.7 million (down 17.51% YoY) and the FY2024 annual result came in at $442.6 million, up 6.33% from the prior year.
- Total Debt retreated to $323.7 million in Q2 2024, from $442.6 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $442.6 million in Q1 2024 to a low of $170.3 million in Q1 2021.
- A 4-year average of $327.7 million and a median of $390.9 million in 2022 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2022 — Total Debt soared 109.85% — and 2024, when it dropped 17.51%.
- Tracing ROIV's Total Debt over 4 years: stood at $204.0 million in 2021, then surged by 94.64% to $397.2 million in 2022, then gained by 7.1% to $425.4 million in 2023, then fell by 23.9% to $323.7 million in 2024.
- The last three Total Debt figures came in at $323.7 million (Q2 2024), $442.6 million (Q1 2024), and $425.4 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 323.72 Mn |
| Mar 31, 2024 | 442.59 Mn |
| Dec 31, 2023 | 425.37 Mn |
| Sep 30, 2023 | 438.44 Mn |
| Jun 30, 2023 | 392.41 Mn |
| Mar 31, 2023 | 416.24 Mn |
| Dec 31, 2022 | 397.16 Mn |
| Sep 30, 2022 | 390.75 Mn |
| Jun 30, 2022 | 391.06 Mn |
| Mar 31, 2022 | 210.03 Mn |
| Dec 31, 2021 | 204.04 Mn |
| Sep 30, 2021 | 199.87 Mn |
| Jun 30, 2021 | 186.35 Mn |
| Mar 31, 2021 | 170.28 Mn |